We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
+$967K
Cap. Flow %
0.05%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.19%
2 Healthcare 13.52%
3 Industrials 0.13%
4 Consumer Staples 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DBVT
301
DBV Technologies
DBVT
$745M
-7,000
Closed -$2.28M
EW icon
302
CALL
Edwards Lifesciences
EW
$49.3B
-7,431
Closed -$21.9M
EW icon
303
PUT
Edwards Lifesciences
EW
$49.3B
-6,603
Closed -$19.4M
GILD icon
304
CALL
Gilead Sciences
GILD
$182B
-8,440
Closed -$77.5M
GILD icon
305
PUT
Gilead Sciences
GILD
$182B
-50
Closed -$459K
HALO icon
306
Halozyme
HALO
$12.3B
-60,000
Closed -$592K
HRTX icon
307
CALL
Heron Therapeutics
HRTX
$59.9M
-126
Closed -$239K
IONS icon
308
Ionis Pharmaceuticals
IONS
$8.55B
-7,002
Closed -$226K
JNJ icon
309
PUT
Johnson & Johnson
JNJ
$642B
-2,061
Closed -$22.3M
LAB icon
310
Standard BioTools
LAB
$273M
-139,506
Closed -$1.13M
LPCN icon
311
CALL
Lipocine
LPCN
$18.7M
-21
Closed -$355K
MNKD icon
312
CALL
MannKind Corp
MNKD
$1.21B
-1,200
Closed -$966K
NBIX icon
313
Neurocrine Biosciences
NBIX
$16B
-70,000
Closed -$3.22M
NSPR icon
314
InspireMD
NSPR
$37M
-1
Closed -$399K
NTRA icon
315
Natera
NTRA
$47.4B
-69,272
Closed -$771K
OMER icon
316
CALL
Omeros
OMER
$1.26B
-415
Closed -$637K
PLUR icon
317
Pluri
PLUR
$15.3M
-3,138
Closed -$404K
PRTA icon
318
Prothena Corp
PRTA
$458M
-40,000
Closed -$1.65M
RGLS
319
PUT
DELISTED
Regulus Therapeutics
RGLS
-5
Closed -$398K
SENS icon
320
Senseonics Holdings Inc
SENS
$461M
-7,695
Closed -$440K
SGMO
321
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
-134,500
Closed -$857K
SPY icon
322
State Street SPDR S&P 500 ETF Trust
SPY
$803B
-108,899
Closed -$22.6M
SVRA icon
323
Savara
SVRA
$1.1B
-55,391
Closed -$1.36M
TNXP icon
324
CALL
Tonix Pharmaceuticals
TNXP
$204M
0
-$36K
TVTX icon
325
Travere Therapeutics
TVTX
$6.2B
-156,774
Closed -$2.54M

Similar funds

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management's Q2 2016 filing shows 94 new, 95 increased, 80 reduced and 99 closed positions. Its largest new stake was Abbott: 264,700 shares worth $10.4M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 86% of assets, up from 78% a quarter earlier, followed by Healthcare and Industrials.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.